Stay updated on 89Zr-Pembrolizumab in NSCLC Clinical Trial
Sign up to get notified when there's something new on the 89Zr-Pembrolizumab in NSCLC Clinical Trial page.

Latest updates to the 89Zr-Pembrolizumab in NSCLC Clinical Trial page
- Check3 days agoChange DetectedThe footer revision was updated from v3.6.0 to v3.6.2, indicating a minor build update. No content or functionality changes are introduced on the study details page.SummaryDifference0.1%

- Check10 days agoNo Change Detected
- Check17 days agoChange DetectedThe page adds new navigation/help sections (How to Read a Study Record, Common Questions, How to Join a Study) and updates the Intervention/Treatment label; the revision tag changes from v3.5.5 to v3.6.0, and an investigator credit for Prof. dr. E.F. Smit is added while the combined investigator line is removed.SummaryDifference2%

- Check24 days agoChange DetectedThe page revision label changed from v3.5.4 to v3.5.5, indicating a new version of the page. This update appears to be a maintenance/version update rather than a modification to study data or public content.SummaryDifference0.1%

- Check46 days agoChange DetectedThe page's revision tag was updated to v3.5.4, indicating a small documentation or backend update. The visible study information and layout remain unchanged.SummaryDifference0.1%

- Check67 days agoChange DetectedThe ClinicalTrials.gov page revision label updates from **v3.5.2** to **v3.5.3**, indicating a site/version release with no change to the study’s informational content.SummaryDifference0.1%

- Check74 days agoChange DetectedRevision updated from v3.5.0 to v3.5.2.SummaryDifference0.1%

Stay in the know with updates to 89Zr-Pembrolizumab in NSCLC Clinical Trial
Enter your email address, and we'll notify you when there's something new on the 89Zr-Pembrolizumab in NSCLC Clinical Trial page.